Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation.

[1]  S. Solomon,et al.  Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.

[2]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[3]  K. Khunti,et al.  Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes , 2020, Annals of Internal Medicine.

[4]  L. Tian,et al.  On the empirical choice of the time window for restricted mean survival time , 2020, Biometrics.

[5]  Lee-Jen Wei,et al.  Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. , 2019, Circulation.

[6]  L. Sharples,et al.  Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[7]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[8]  Jennifer R. Rider,et al.  Restricted Mean Survival Times to Improve Communication of Evidence from Cancer Randomized Trials and Observational Studies. , 2019, European urology.

[9]  H. Ribaudo,et al.  The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial , 2019, Journal of acquired immune deficiency syndromes.

[10]  B. Rachet,et al.  Summarizing and communicating on survival data according to the audience: a tutorial on different measures illustrated with population-based cancer registry data , 2019, Clinical epidemiology.

[11]  L. Trinquart,et al.  Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Mack,et al.  Transcatheter Mitral‐Valve Repair in Patients with Heart Failure , 2018, The New England journal of medicine.

[13]  W. Li,et al.  Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Uno,et al.  Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  S. Solomon,et al.  Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. , 2018, Journal of the American College of Cardiology.

[16]  H. Uno,et al.  Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. , 2017, JAMA cardiology.

[17]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[18]  Daniel D. Drevon,et al.  Intercoder Reliability and Validity of WebPlotDigitizer in Extracting Graphed Data , 2017, Behavior modification.

[19]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[20]  L. Trinquart,et al.  Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Lu Tian,et al.  Strmst2 and Strmst2pw: New Commands to Compare Survival Curves Using the Restricted Mean Survival time , 2016 .

[22]  Patrick Royston,et al.  Meta‐analysis of time‐to‐event outcomes from randomized trials using restricted mean survival time: application to individual participant data , 2015, Statistics in medicine.

[23]  H. Uno,et al.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. , 2015, Annals of internal medicine.

[24]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[25]  Yoshiaki Uyama,et al.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Patrick Royston,et al.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome , 2013, BMC Medical Research Methodology.

[27]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[28]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[29]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[30]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[31]  Katrina Armstrong,et al.  Using survival curve comparisons to inform patient decision making , 2001, Journal of General Internal Medicine.

[32]  Jessica S. Ancker,et al.  The Practice of Informatics: Design Features of Graphs in Health Risk Communication: A Systematic Review , 2006, J. Am. Medical Informatics Assoc..

[33]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[34]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[35]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[36]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[37]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[38]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[39]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[40]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[41]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[42]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[43]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.